Medical & Biotech: Neuren Pharmaceuticals’ Rett syndrome drug Daybu (trofinetide) has cleared a major hurdle in Europe, with the EMA’s CHMP issuing a positive opinion after re-examination; if the European Commission follows, it would become the first EU-authorised treatment for neurobehavioral symptoms in Rett for patients aged five and up, with milestone-linked upside for Neuren and partner Acadia. Iceland & Energy Tech: Kingfish Company says it has closed a EUR 21m private placement as part of restructuring to simplify its capital and cut net debt, and it flags Eyrir Invest (Iceland-based) as its largest shareholder after the deal—tying the funding to recirculating aquaculture system (RAS) technology. Arctic Climate & Power: A new analysis suggests Arctic rivers—even very cold ones—could support hydrokinetic turbines to replace some diesel generation for remote communities, aiming to cut costs and pollution. Climate Signals for Europe: Researchers link Central European droughts to winter conditions months earlier, driven by the North Atlantic Oscillation’s storm-track pattern. Local Tech Policy Watch: Iceland’s digital shift continues, with reporting that the country has switched off 2G and 3G networks. Youth & Gambling: A University of Iceland survey finds around 40% of upper secondary students in Iceland gambled in the past year, with loneliness and mental wellbeing flagged as key risk factors.